Difference between revisions of "Team:AQA Unesp"

Line 15: Line 15:
 
}
 
}
 
function changeText3() {
 
function changeText3() {
−
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d1/T--AQA_Unesp--actuating.png' id='man_title3'  height="70" width="70">We need our insulin to be secreted by our bacteria so the insulin gene will have an secretion signal sequence called usp45 which allows L. lactis to secrete proteins. The insulin that we will be using is a single-chain analog called SCI-57 that can be produced by bacteria and maintain its biological activity. Once the insulin is out, it needs to be absorbed by the intestinal epithelium, so our insulin will be associated with cell-penetrating peptides (CPPs) that allow the uptake of the insulin, which will reach the blood and then perform its biological function.";
+
document.getElementById("text").innerHTML="<img src='https://static.igem.org/mediawiki/2017/d/d1/T--AQA_Unesp--actuating.png' id='man_title3'  height='70' width='70'>We need our insulin to be secreted by our bacteria so the insulin gene will have an secretion signal sequence called usp45 which allows L. lactis to secrete proteins. The insulin that we will be using is a single-chain analog called SCI-57 that can be produced by bacteria and maintain its biological activity. Once the insulin is out, it needs to be absorbed by the intestinal epithelium, so our insulin will be associated with cell-penetrating peptides (CPPs) that allow the uptake of the insulin, which will reach the blood and then perform its biological function.";
 
}
 
}
 
function cleanText() {
 
function cleanText() {

Revision as of 03:01, 30 June 2017



iGEM AQA_Unesp
.

Team: AQA_Unesp

Treating diabetes with probiotics


In our first time ever participating in iGEM, our project is to develop a new treatment for diabetes mellitus type 1 (DM1). We want to engineer a Lactococcus lactis strain to live in the human gut and produce an insulin analog that can be absorbed by the intestinal epithelium. The number of DM1 patients and deaths due to DM1 is increasing every year and we want to make those people’s life better: no more several insulin injections in a single day! Our engineered L. lactis will produce a single-chain insulin analog associated with cell-penetrating peptides (CPPs) that facilitate the uptake of insulin by the intestinal epithelium. The expression of insulin will occur under a glucose control built using the catabolite repression system of gram-positive bacteria along with regulation by a small RNA. Mouse over the image to learn more!

Team: AQA_Unesp